

A thimble full of this...

Living Metal Sells for **\$141,748**



- One tiny company has a monopoly on it
- Its sales are set to surge 24,474% over the next 15 months
- And it could go public on the NASDAQ as soon as August 31st

Picture a thimble... just big enough to cover the tip of your finger.

If you filled that thimble with pure gold, you could sell it for more than \$1,300.

If you filled it with platinum, it would now be worth over \$1,400.



And that same thimble, filled with diamonds, would sell for north of \$11,500.



For a thimble full of *anything*, that's a lot of money.

But it's just a drop in the bucket compared to what I'm going to show you today.

Inside the thimble on your screen now, you'll find one of the most rare materials on the planet.

Containing both biological and metallic properties, it's classified as a Living Metal.

And it can only be found in one small stretch of underwater territory, 14 miles off the coast of the Channel Islands.



However, its scarcity is not why a thimble full of this Living Metal is currently selling for \$141,748.



This is...

An international panel of 15 doctors from the University of Liverpool, London's Institute of Neurology, and the Alzheimer's Institute in the U.S. have collectively analyzed this Living Metal.

They officially concluded that it can "***prevent and possibly treat Alzheimer's dementia.***"

But that's just the beginning.

At this very moment, 124 advanced clinical trials are progressing rapidly.

They're taking place at Penn, Baylor, Loyola University, UCLA, and the most cutting-edge medical facilities.

And they're all coming to the same conclusion.

This Living Metal can literally reprogram the human immune system to such a degree...

It can make us ***totally*** immune – ***totally*** impervious – to some of the most dangerous diseases known to man.

Which is why, it should come as no surprise, that even though sales of this Living Metal are only \$2.63 million...

The story moving forward is completely different.

Today, every major pharmaceutical company is fighting to acquire as much as they possibly can.

I'm talking about:

Bayer, Pfizer, GlaxoSmithKline and a Half Dozen Others...

**Right Now They're Paying \$141,748 For Just a
Thimble Full of This Living Metal...**

And They Consider it a Bargain.

That's because the FDA is set to green-light a series of Living Metal treatments that could solve the greatest medical challenges of our generation.

And estimates suggest sales of this breakthrough are about to aggressively rise as much as 23,474% in the next 15 months.

As I'm going to show you today...

**This Living Metal is Looking at Potential Sales of
\$620 Million Per Year.**

And One Company Has a Monopoly on it.

My name is Michael Robinson.

Over my 35-year career, I've worked as an advisory board member for one Silicon Valley venture capital firm and as an advisor to the venture capital and technology industry.

I specialize in identifying early-stage funding opportunities.

In 1985, I was granted early access to sensitive military projects tied to President Reagan's Strategic Defense Initiative.

In the late 1990s, I met with a group of technology leaders just a few miles north of Silicon Valley, and we mapped out what would become the \$160 billion "cloud computing" industry.

After the millennium, I worked with Dave DeWalt the former CEO of McAfee on cyber security technologies, just before Intel acquired that company for \$7.8 billion.

I was involved in the early stages of a technology called MEMS, or "microelectromechanical systems."

These tiny sensors are able to detect the precursors for cancer and heart disease, decades before they threaten your body.

In 2006, the company, along with their technology, was sold for \$126 million.

And today, it's at the forefront of what is about to be a \$7 trillion global industry.

Now, while deals like that have been very lucrative...

Never in My Career Have I Come Across a Venture Like the One I'm About to Share With You

Before I begin, let me tell you that there is a catch.

The company who holds a monopoly on this Living Metal is not listed on the New York Stock Exchange or NASDAQ.

You won't find it on the OTC Pink Sheets.

And you won't find it on the London, Tokyo, or any of the major foreign exchanges.

In fact, of the 27.8 million U.S. companies... both public and private...

There are only 87 with the unique classification this biotech firm holds.

So what you are looking at is the same kind of potential you'd see in an early-stage, venture capital opportunity.

The ones usually available only to the venture capital firms who get in pre-IPO.

That's why you never hear stories of a public company's revenue shooting up 23,000% in just 15 months.


Everyday investors are nowhere near when that profit spike occurs.

Fortunately, I've held a series of private meetings with the CEO of this company.

In fact, you're going to hear from him numerous times throughout this presentation.

We're going to walk you through the medical studies and clinical trials for this Living Metal.

We're even going to take you on a virtual tour of the facility where it is being developed.



But here's the most important point we're going to cover.

I've developed a package that reveals everything you need to know about this incredible company and its monopoly over this Living Metal.

And I'll reveal how you can become what's called a "round lot" investor BEFORE it "goes public" on the NASDAQ.

Which the CEO himself believes could happen as soon as August 31st.

Shortly after, we expect to see the conclusion of late-stage clinical trials that will propel at least 7 drugs that integrate this company's Living Metal to commercialization.

These treatments will drive revenues from \$2.63 million to \$620 million PER year and possibly much higher.

In other words, this company could see its sales grow 23,474% over the next 15 months.

And the SEC documents I'll show you in a moment strongly suggest the same because, in anticipation of a NASDAQ listing, they've already classified it as an "emerging growth company."

But there is even more in play.

Because of the lifesaving impact of this company's Living Metal – our government offers a unique incentive; a very special tax credit.

This alone has the potential to put thousands, even tens of thousands of dollars, back into your pocket, on top of an already historic windfall.

All courtesy of Uncle Sam. All because **everybody** wants this company to succeed.

So, at the end of this presentation I'll show you how to claim a special package via FedEx overnight.

It contains a time-sensitive "*Money Morning* Prospectus" on this rare venture.

Plus, you'll receive important paperwork you will need to review in order to make a decision on whether this opportunity is right for you.

So let's jump into the details.

Here's why this Living Metal may be...


The Medical Discovery of the Century

Your immune system, when functioning properly, can take on almost any virus, bacteria, or toxin.

But it has one major flaw.

Immune systems are terrible at detecting problems that start ***inside our bodies***.

Which is **exactly** where Alzheimer's disease begins – with a genetic mutation in certain brain cells.



This creates what's called Amyloid-beta – or $A\beta$ – plaque.

$A\beta$ plaque is an amino acid that binds to your memory receptors.

When it builds up on your brain's hippocampus, it clogs your memory circuits.

Now, to your immune system the mutated cells that create $A\beta$ plaque appear to be perfectly normal.

In other words...

Your Immune System Can't Tell Which Cells Are Keeping You Alive and Which Could Be Giving You Alzheimer's...

And That's Where This Living Metal Comes Into Play.

Its scientific name is *Megathura Crenulata hemocyanin*.

We'll call it MCh for short.

MCh is a very rare type of protein that has both biological and metallic properties.


In other words, it's part membrane – just like your blood cells – and part metal.

And that combination gives it a unique ability.

This Living Metal, MCh, Can Actually Reprogram the Immune System of Those Suffering From Alzheimer's.

Let me show you how it works.

Doctors are now rendering cells with the Alzheimer's disease-causing, A β mutation harmless.



They take each altered cell, attach it to this Living Metal, and inject it into your body.

That's when it goes to work.

This Living Metal begins to reprogram your immune system in 5 steps that are set in motion in a fraction of a second.

Step 1: Through a part of its metallic structure called epitopes, it stimulates your immune system into creating a massive amount of B and T Cells.



These are the cells in your body that defend against viruses, bacteria and other threats.

Step 2: These cells, instantly recognize the MCh, Living Metal, as a foreign body, and initiate a powerful attack against it.

But, since it's part metal, MCh can survive conditions that would kill off normal cells.

The immune system can't hurt it.

Now, if a live bacteria or virus were spreading throughout your body, it would destroy a large portion of your new immune cells.

But this Living Metal isn't a live bacteria, or virus. Your immune system just **thinks** it is.

So MCh doesn't fight back.

It lets your immune system build its attack.

And that leads to...

Step 3: Your B and T Cells, having failed to eliminate the Living Metal, now search for a new way to defeat these "invaders."


And guess where they find it?

The A β mutation that's been attached to this Living Metal.

Your immune system now sees this deadly mutation, not as a naturally occurring part of your body like it previously did, but as a foreign invader.

Step 4: Your B and T Cells adapt. They reprogram to become hyper-aware of that mutation.

Step 5: Your immune system eradicates these mutations...



So A β Plaque Never Forms and Dementia and Alzheimer's Never Take Hold

And for those who already are stricken with these diseases, this Living Metal can destroy the source of it, so a recovery is now possible.

124 advanced clinical trials are already being accelerated at facilities across the world, including the Medical University of Vienna in Austria.

And here in America, doctors from Penn, Baylor, Loyola University, and UCLA are leading their own initiatives.

Dr. Bruce Yankner is a member of the original research group, which identified the toxic proteins that lead to Alzheimer's.

He recently stated that, "*It's an amazing idea that neurons that you're born with will function for 100 years or more.*"

Dr. Yankner is saying we are on the verge of having treatments that will allow our brains to maintain peak health and clarity, throughout our entire lives.

And without the threat of Alzheimer's, or dementia.

Right now, through the federal "Brain Activity Mapping Project," the NIH is investing in research like this to the tune of \$100 million a year.

And the major pharmaceutical and biotech companies are investing much more...

Even at a price tag of \$141,748 for a thimble full of this Living Metal.

But there aren't an unlimited number of "thimble-fulls" to be had, because one company has a monopoly on their production.

And the reason why may be the most incredible part of this story.

This Living Metal Can Only Be Harvested From the Blood of One Marine Animal.

It's called *Megathura crenulata*.

Megathura crenulata is a Gastropod (which is the same family as snails).



When they're hatched, they are so small, you can only clearly see them through a microscope.

Now, when they're fully mature, which takes three years, these animals weigh about a pound

each.

And they're incredibly rare – existing in just one part of the world...

Right here, on a small stretch of ocean off the coast of Southern California.



They live nowhere else on this planet.

And the natural population of *Megathura crenulata* is declining rapidly.

So much so, that they're now a protected species, meaning you need special permits to collect them.

Which is why, after they've been caught, extracting the Living Metal takes a non-lethal process that requires pinpoint accuracy.

It's also why a single thimble full of MCh contains small blood donations from 72 fully grown *Megathura crenulatas*.

And there are no substitutes because...

This Living Metal Can't Be Synthesized.

The technology to artificially create it does not exist.

It's too complex.

It simply can't be done.

That's the reason this company was handed its monopoly on a silver platter.

You see, 15 years ago, this Living Metal had already been discovered inside the blood of the

Megathura crenulata. And big pharmaceutical companies were eager to start human clinical trials.

However, the FDA had concerns that these drug makers wouldn't be able to extract these animals from their natural habitat without killing off the species entirely.

And in doing so, eliminating the only source of the lifesaving MCh hidden in their blood.

This fear was also shared by the pharmaceutical companies themselves.

So together, they identified the one expert in marine biology who could solve this problem.

He's now the founder of the biotech firm that controls the world's supply of this Living Metal.

And I'm going to let him tell you about the first time a Maryland pharmaceutical company – Intracel – came to him to get their MCh for a Phase III bladder cancer trial.

That company was developing a bladder cancer vaccine and they actually had a Phase III clinical trial they wanted to launch in the U.S. and the FDA was concerned – how can a company producing a pharmaceutical product assure that those animals are suitable? And the company simply couldn't answer that question.

And that company also had a concern over the sustainability of the supply because they felt that the bladder cancer drug was going to require as much as a kilogram of protein annually and their divers were not able to produce that much, reliably.

So what I did for that company was to get the FDA to release their drug from clinical hold.

And then I developed a plan for that company to support the commercialization of its bladder cancer vaccine.

And then I developed and patented the method to bring animals on shore and acclimate them to a culture environment, non-lethally extract the protein so we could use the same animals over and over again, and developed a seawater system that could grow those animals in that environment, eliminate bacterial and viral contaminants, and non-lethally extract protein from the same animal which allowed traceability from the finished product back to the source animals.

As the CEO of this biotech firm just explained, he was called on to create a process for safely extracting this Living Metal from the blood of the *Megathura crenulata*.

That's exactly what he did.

And bladder cancer vaccines using this Living Metal are now being introduced in Europe and Asia.

The story he just shared with you quickly became a common one.

You see, nearly every major pharmaceutical company needed an FDA-approved source of MCh for their own clinical trials.

And our government realized this.

Which is why the National Institute of Health, National Cancer Institute, and National Science Foundation each fast-tracked a series of grants for this CEO totaling \$7.1 million.

Then, he was granted special permits to operate on restricted coastal property, right next to the *Megathura crenulata's* natural habitat.

The CEO spent the next 10 years perfecting his custom aquaculture facility that perfectly recreated this environment.

He's now going to give you a walkthrough of this facility.

We maintain a facility with the capacity to produce roughly a 1000 grams, or 1 kg of KLH. It requires roughly 1000 mature adult animals.

It requires 20 tanks to do that. And we have a pumping capacity in excess of 1 million gallons of seawater a day.

In its entirety the facility includes production tanks for maintaining the adult animals.

We also have a marine hatchery facility that allows us to spawn adults and produce 10,000 to 50,000 new juveniles every year that will allow us to scale to support some of the high-volume vaccines such as Alzheimer's.

As our population of juveniles grows, we simply need to add additional production tanks, and we have the pumping capacity to do that.

Today, the campus this biotech firm is located on – and what's inside it – is so important to our government that it's guarded 24 hours by U.S. Marines in a secure facility.

What this CEO has developed is a way to non-lethally extract a rare protein that is going to lead to some of the most important medical breakthroughs in history...


From an animal that's at risk of falling into the endangered species list.

And he's found a way to breed the animal, the *Megathura crenulata*.

Which is important, because there are only about 120,000 of them left in the wild.

But, as you just saw, this company already has dozens of tanks full of *Megathura crenulata*.

In fact, they have about 70,000 domesticated animals in their aquaculture facility.



37% of the World's *Megathura Crenulata* Are in This Company's Tanks

And as the CEO just explained, they have the ability to hatch up to 50,000 more a year.

Plus, this company has one more critical advantage.

Because they've created a controlled environment, they can trace every single gram of their MCh back to the original animal it was first extracted from.

So inside a thimble full of this Living Metal, 72 of those creatures can each be identified by their specific blood.

This allows for expedited FDA approval on all drugs using MCh – which there soon will be a lot of.

To this point I've only shared with you the miraculous results this Living Metal has produced for Alzheimer's.

In a few moments, we're going to examine the other diseases it's being applied to.

And here's why that's possible.

The founder of this biotech firm is a marine biologist by trade.

So when he was forming his company, he went out and recruited the top scientists and medical minds across the fields most likely to be impacted by this Living Metal.

Today, his scientific board includes:

- Dr. Andrew Saxon, the UCLA immunologist who first discovered and alerted the CDC to the AIDS virus in the early 1980s.
- Dr. Malcom Gefter the leading biochemist at both MIT and Columbia University who also worked at the MRC laboratory in the UK that originally pioneered DNA sequencing.
- Dr. Daniel Morse who has been named one of the top 50 technology innovators by Scientific American, for his groundbreaking work on nanotechnology.

So you can see why the government and the major pharmaceutical companies essentially granted this biotech firm a monopoly over this Living Metal, MCh.

And this firm will be able to control that monopoly for at least a decade.

Which is why both the CEO and I are confident that his company will surge from \$2.63 million in sales, to potentially \$620million within 15 months.

That's a 23,474% spike in revenue.

You see, besides Alzheimer's disease, this Living Metal could be...

A True Cure For Cancer

Cancer is a fast-growing mutation of your body's own cells.

And because they're your own cells, your immune system is tricked into believing they belong there.

In other words...

Cancer Blinds Your Immune System.

This Living Metal Gives it Sight.

You've probably heard stories of unexplained remissions.

Terminal cancer patients with just weeks to live... who doctors say are too far gone to be helped by drugs.

Yet somehow, they suddenly go into remission.

Many people attribute this to a miracle. And it very well may be since science can't explain *why* it happens.

But we do know *what happens*.

Somehow, the immune system learns to recognize and eliminate the cancer cells.

So, for a few fortunate folks, their immune systems are miraculously reprogrammed.

Scientists Have Discovered They Can Use This Living Metal to Force This Reprogramming to Happen.

The top cancer research centers, including Memorial Sloan Kettering Cancer Center and Roswell Park Cancer Institute, have extremely promising clinical trial results.

Much of the initial success involved cancer patients already in remission.

In clinical trials, doctors attached this Living Metal to their patients' own deactivated cancer cells and injected the combination back into their body.

What the trial determined is that their immune systems were quickly able to stop the cancer dead in its tracks.

This treatment is already approved and available in Europe and Asia.

And thanks to its initial success, *Popular Science* has declared that this Living Metal "**Could Cure Cancer.**"

But that's just the beginning.

Using this same method, doctors are developing drugs that make you immune to almost every form of cancer BEFORE you're stricken with it.

After conducting a small, 6-person study with MCh, Harvard Medical researchers are now reporting that:

"All six patients were completely [immunized] by treatment containing MCh."

Translation: This Living Metal can conquer cancer.

And it's not just cancer and Alzheimer's disease.

This Living Metal is Succeeding Where Antibiotics Fail

If you haven't heard of *Clostridium difficile*, or C. Diff, by now, you will soon.

It's a bacterial infection that affects about 500,000 patients a year... and incidents are on the rise.

A mild case causes severe diarrhea, pain and fever.

If left untreated, the bacteria will eventually eat a hole through its victims' intestines.

In America alone, about 14,000 people die every year from this terrible condition.

Now, for decades it's been successfully treated with a 10-day regimen of antibiotics.

But recently, a new antibiotic-resistant strain of this bacteria has emerged.

The drugs don't work.

So Without a New Treatment, C. Diff Could Become Exponentially Deadlier.

This Living Metal, MCh is *That Treatment.*

It has just successfully undergone an advanced medical trial.

Because of the growing epidemic of C. Diff infections around the country, the company expects it to be fast-tracked through the FDA.

It could be in use here as early as 2015.

But it's already about to be implemented in Asia.

I happen to know of a specific licensing deal with this company that's going to bring this treatment to Taiwan in particular.

Now, believe it or not, this incredible Living Metal still has more to offer.

It Could Stop a Pandemic

Right now, the CDC is closely watching a dangerous outbreak of the Ebola virus in West Africa.

Ebola is a particularly "intelligent" virus.

When it first enters the body, it tricks our immune systems into believing it belongs there.

And it doesn't actually begin to attack until it's replicated itself and has invaded every last organ.

That's when it activates.

Which is why up to 90% of those infected will die.

Historically, outbreaks have been limited to remote forest towns and villages.

The current one, however, is happening in the city of Conakry, Guinea.

Conakry has a population of 2 million people and it is home to a major international airport.

Now, because Ebola lies dormant in its victims for up to 21 days...

An infected person could be on a flight today, landing in New York, Chicago, or Los Angeles... before traveling to any number of small towns in America.

This is a very, very real threat.

Fortunately, this Living Metal could be the solution.

Here's how.

By binding a deactivated Ebola molecule to this Living Metal, we could potentially stop a worldwide pandemic.

An advanced medical trial published in the *Journal of Virological Methods* using MCh has already led to this conclusion.

Everything I've shown you today is just the tip of the iceberg.

Demand for MCh is starting to grow exponentially...

There Are 124 Treatments Using This Living Metal Currently Undergoing Clinical Trials.

- Alzheimer's disease
- C. Diff
- Rheumatoid arthritis
- Asthma
- Crohn's disease
- Multiple Sclerosis
- And HIV

If you recall, one of the developers of this Living Metal breakthrough, was Dr. Andrew Saxon, who first discovered the AIDS virus.

And now this same medical pioneer is at the forefront of what may be its cure.

Plus, there are also MCh-based treatments progressing through clinical trials for 10 forms of cancer.

- Melanoma
- Breast cancer
- Bladder cancer
- Non-Hodgkin's Lymphoma
- Colorectal cancer
- Prostate cancer
- Pancreatic cancer
- Lung cancer
- Kidney cancer
- And brain cancer...

Going just by the raw stats, this is great news...

The NIH currently lists 10 of those 124 clinical trials using MCh as Phase III or finished Phase III and awaiting publication.

Now, here's why that is important.

According to a study done by Tufts University professors, by the time a clinical trial gets to Phase III, the odds of success are incredible.

Two out of every three drugs that reach this milestone will be brought to commercialization... Meaning doctors will be able to treat patients with them.

But the odds are even greater for large molecule drugs.

And as a metallic protein, this Living Metal, MCh, falls into this category.

Here, more than 70% of Phase III drug trials lead to commercialization.

So again, looking at pure statistics...

There Will Soon Be *At Least 7* Drugs Using This Living Metal, MCh, on the Market

And when I say soon, we're talking as quickly as the next 15 months.

So, as each trial success is announced... we're looking for a big move in the small biotech firm that currently has a monopoly on this Living Metal.

Now remember, their sales have totaled \$2.63 million. So this will put everything in perspective.

If just one cancer treatment reaches commercialization, we're looking at annual MCh sales of \$40 to \$60 million.

With one success in immunology, this company's portion of the sales could be \$10 to \$15

million a year.

And for just one treatment for infectious disease like, C. Diff, we could see sales of \$100 million to \$150 million a year.

But these are just a few pieces of the pie. I'm now going to hand it over to this biotech firm's CEO.

He's going to walk you through their most exciting revenue projections.

The protein is really significant because it's used in so many indications as a carrier protein for drugs that are well advanced in clinical trials.

They include indications such as Rheumatoid arthritis.

In annual sales it represents \$10-12 billion. And it has leading pharmaceutical companies involved such as Abbott, Johnson and Johnson, Amgen...

And our clients forecast for annual sales suggest that a fully developed drug could generate \$200 million for the protein component alone.

Other indications such as Alzheimer's, which is a \$170-billion-dollar-a year drug opportunity – again with companies like Pfizer, Johnson and Johnson and Lilly – companies developing therapies using our product suggest that the sales opportunity could be \$200 million as well.

These are based on customer forecasts of their drug sales and our calculation of what the protein sales component would look like.

In indications such as Autoimmune disease – which includes indications like Crohn's disease, lupus disease – represent a \$40-45 billion market opportunity.

A success in that market could represent as much as \$100 million in sales.

And in every one of those indications, there are drugs that are currently in the clinic that are showing good results.

Indication	Large Biopharma Involvement	Potential Annual Revenues
Cancer	Roche, Sanofi, GSK	\$40 - 60 Million
Immune Function	N/A	\$10 -15 Million
Infectious Diseases	Pfizer, Sanofi, Merck	\$100 - 150 Million
Rheumatoid Arthritis	Abbott, J&J, Amgen	\$200 Million
Alzheimer's	Pfizer, J&J, Lilly	\$200 Million
Autoimmune Diseases	Abbott, Amgen, Bayer	\$70 - 100 Million

What the CEO and I just outlined is a conservative estimate of what's coming.

At the very least, we expect to see a spike to \$200 million in sales.

That's a fast 7,500% from just the first drug approval.

And then, in a best-case scenario, if just one drug in each of these categories reaches commercialization, we're looking at historic 23,474% growth in revenue.

Sales of this Living Metal protein, MCh, will rise from \$2.63 million to \$620 million a year. And that's based off the **low-end** projections from their customers.

As I mentioned at the beginning of this presentation, this is the kind of venture capital opportunity I've targeted my whole career...

Companies that have early-stage and pre-IPO-like growth potential. But in this case, there is one major difference.

The deals I've negotiated in the past were specifically for Silicon Valley venture capital firms.

What's in play with *this venture* is totally unique...

You see, even though this biotech firm is not publicly listed on any major U.S. exchange, and it's not an OTC Pink Sheet stock...

I have developed a package that reveals a unique way for you to become what's called a "round lot" investor in this company.

Here's how you can understand what a round lot investor is.

Ownership in every company, both public and private, is separated into pieces.

These can be held by one person or many people.

A round lot investor is someone who buys a block of 100 pieces of a company.

In the venture I'm presenting to you today, you can secure each round lot for \$100.

Now, you can buy one, two, three... whatever number you're comfortable with.

However, I'm recommending that those who can, buy 20 round lots, or 2,000 pieces of the company.

Per NASDAQ's corporate governance rules 4350 and 4351, a company looking to get listed on this exchange is required to have at least 12,500 outstanding round lots.

That's in addition to those held by owners and directors.

So to be clear, the CEO, and the board of directors... Their round lot holdings do not count toward that 12,500 figure.

Now, let's talk about what happens when this company is listed on the NASDAQ.

Each round lot you hold will be transferred into 100 shares of company stock under its new ticker.

It'll be just like every other stock you hold in your portfolio.

And here's another NASDAQ requirement that's pretty exciting.

When a company is listed on this exchange, its share price in most cases **MUST** start at \$3 or higher.

That means, by the time the NASDAQ listing occurs, each round lot you purchase today for \$100, could be valued at \$300 or more.

A 200% spike.

And that's before a single drug hits the market. So I'm not even thinking about 200% for this play.

Especially when you consider this...

As Director of Venture Capital and Technology Investing here at *Money Morning*, I've been following this Living Metal company since well before I started meeting with its CEO.

And before I brought this opportunity to you, I wanted to make sure this was the real deal.

So what the team and I at *Money Morning* did was first measure the impact of this Living Metal company on its current customers.

And that led us to Celldex Therapeutics – a key player in the field of Immunology.

Celldex is a public company listed on the NASDAQ.

We recommended our members invest in it after it secured a small supply of this Living Metal for use in a clinical trial they initiated for a brain cancer treatment.

Shortly after, Celldex's stock price soared and members saw a chance at 629% max gains.

Just think about that for a second.

Celldex Therapeutics acquired a small amount of this Living Metal, MCh, for a single clinical trial – and it was a massive catalyst that helped shoot its stock price up 629%.

Now imagine what's in play for the biotech firm that has a monopoly on this Living Metal's entire supply.

There are 124 clinical trials progressing rapidly right now.

The statistics clearly show that conservatively speaking, 7 of these trials should result in treatments reaching commercialization.

So, as each treatment with MCh – this Living Metal – hits the market...

I fully expect their stock price to surge past \$10, \$25, even \$50 per share...

Making each of those \$100 round lots you started with worth \$1,000... \$2,500... or even \$5,000 apiece.

And I don't anticipate it stopping there. Not by a long shot.

23,474% is my target here.

Which is why I've prepared – for immediate release today – a *Money Morning* Prospectus on the company that has a monopoly on this Living Metal's supply.

I want to FedEx overnight this *Money Morning* Prospectus to you right after this presentation, because we don't have much time to waste.

This Company is About to "Go Public" On The NASDAQ Faster Than Anyone Expected

In an exciting SEC filing, this biotech firm was classified as an "Emerging Growth Company" under the Jumpstart Our Business Startups Act – or JOBS Act.

The reasons stated for this classification specifically mentioned one of its health applications in particular... cancer.

The SEC document described this Living Metal as "*potentially immunogenic.*"

That it "*is the basis for a proven strategy for a new class of drugs...*"

"For lymphoma, bladder, breast, colon, and other cancers..."

And that it has been "*proven safe in humans.*"

This SEC classification as an "Emerging Growth Company" grants them a 5-year window where they are exempt from a whole host of hurdles that can normally impede a company's rise.

With these hurdles out of the way, as the CEO is about to explain, it can move quicker than most toward launching on the NASDAQ.

We are well advanced in the process and have identified a pathway for listing on the NASDAQ.

A lot of the challenge is to get the timing right. We are advanced in the selection of legal council, identification of the appropriate accounting firms, have retained the appropriate firms to give us the support...

And have initiated all the application activities. For our company it's more likely to be an issue of timing rather than certainty.

You know, we're on that pathway, well advanced, and are likely to see that within the next few weeks to couple of months.

The CEO told me a good target date for his company's launch on the NASDAQ is August 31st.

However, it could happen even faster which means you have to act TODAY to be sure you're not left out on the initial profits.

Now with an opportunity of this nature you will undoubtedly have questions.

The *Money Morning* Prospectus will answer them all for you.

But I do want to take some time to focus on four of them here so you can decide if this is right for you.

Question #1: Are There Any Special Requirements Necessary to Take Part?

The simple answer, to invest in this Living Metals company, is no.

A common requirement in certain unconventional investments is that you need to be an accredited investor.

If you're not familiar with the term, accredited investors need total income of \$200,000 per year, or a net worth of \$1 million excluding the value of their home.

But to be clear, with the opportunity I detail in this *Money Morning* Prospectus you DO NOT – I repeat – DO NOT – have to be an accredited investor.

Now, I recommend for most people that you start with 20 round lots – and as a reminder – when this company is listed on the NASDAQ those 20 round lots will become 2,000 shares on the exchange.

To secure 20 round lots that will cost \$2,000.

However, you could buy a single round lot for \$100...

Or you could even buy partial lots.

Everything is explained in the *Money Morning* Prospectus.

You'll also be provided with phone numbers you can call to place your round lot order.

It doesn't matter if you live on the West Coast, East Coast, or even overseas – you will be given the proper contact information.

Plus, you'll be shown how to secure your position online as well.

It's very simple and it doesn't take much time at all.

Now, although there are no requirements to take part in this opportunity, there are a few steps to take before receiving the *Money Morning* Prospectus itself.

For instance, before I can send it to you, you'll be required to digitally sign a nondisclosure form. This simply states you agree not to share this information with anyone.

We're planning to only send physical copies of this package via FedEx overnight. And you will be required to sign for it when it arrives.

You will not receive a digital copy via email or from a website. That way I can ensure the *Money Morning* Prospectus is not distributed online.

Now before you decide whether you want to receive the *Money Morning* Prospectus you will need an answer to...

Question #2: How Much Risk is Involved With this Venture?

There is no such thing as a risk-free investment and this is no different.

So there are a few specific risk factors I want to address.

For instance, there's a chance that the company won't be listed on the NASDAQ this year.

Now, as you heard the CEO say, it's just procedural from here.

In other words, it's a matter of paperwork.

The SEC already has documentation and is prepared to expedite this company through the listing process.

However, if any of that paperwork isn't perfectly in order, the SEC or the NASDAQ *could* delay the process.

Short term that may hurt the investment.

But long term it won't matter. The profit potential is based on the science, not the SEC.

This company is the only large and sustainable source for this Living Metal, MCh, that is at the center of miraculous treatments for Alzheimer's, cancer, and every other condition we've talked about today.

But even if it's never listed on the NASDAQ, you will still retain your ownership stakes in the company.

And the *Money Morning* Prospectus will show you how to sell them whenever you want.

Here's another risk I want to address.

You might be wondering what would stop this company from diluting the value of your round lots by issuing more of them prior to its listing on the NASDAQ – or by issuing a second offering of shares once it has been listed?

I'll let the CEO answer this himself, because it allows me to mention another feature of the package I put together for you...

Along with the *Money Morning* Prospectus, you will also receive an audio briefing where the CEO and I walk you through every aspect of this opportunity.

This audio briefing will give you even more information to help you make a decision on this venture.

So I'm going to play an excerpt now that specifically addresses the risk of round lot or share dilution.

MR: What are the prospects for keeping the shareholders current? Meaning not getting diluted?

CEO: Right now we've got a strong balance sheet. We've got cash that will take us out 30 months... 30-36 months depending on how we do with our C. Diff project development.

CEO: So we think we're strong.

MR: So no secondary offering, correct?

CEO: That's correct.

Okay, so let's assume this company gets listed on the NASDAQ – that carries its own risk too.

Mainly that it's likely to be volatile at first.

Remember, there are currently 124 clinical trials progressing through FDA examinations that rely on this Living Metal.

Including 10 drugs in Phase III clinical trials. For all drugs, once they reach that phase, the probability of commercialization is 60%.

But for large molecule drugs... and MCh is the largest organic protein known to man... the probability jumps to 70%.

So, we're anticipating on the low end, 7 successes.

But whenever a failure is announced – and they will be announced – it could cause a temporary 20-30% pullback.

However, we're targeting a 15-month window with this opportunity, so the day-to-day volatility is not our concern.

Because even if we only see 1 success in a major disease category over the next 15 months – that's only one out of the 7 we expect... and only a fraction of the 124 total active trials.

That one success alone could cause the revenue of this company to surge more than 3,900%.

So while the volatility does present a risk in the short term, I'm not personally too worried about it given our anticipated investment horizon.

And now that we've addressed risk that leads perfectly to....

Question #3: How Much Money Can I Expect to Make?

Well that depends on how you want to approach this opportunity.

If you purchase round lots today for \$100 each, by the time this company is listed on the NASDAQ at \$3 per share or higher, it could mean a 200% profit.

And you may decide that's enough for your tastes.

You may also decide to exit out after a few successful trials have been announced and sell your shares like you would any other stock on the NASDAQ.

After all, the first successful trial alone could grow the revenue forecasts for this company by 3,900 %.

However, let's assume you want to stay in this venture a bit longer.

Now you've got an even bigger potential payday.

Remember, this company's Living Metal sales have hit \$2.63 million.

Over the next 15 months, with the successful announcements of Phase III trials, this company could see the following revenue streams:

- \$10-\$15 million from their immunology therapy.
- \$40-\$60 million for their cancer treatments...
- \$100-\$150 million from their C. Diff treatment...
- \$200 million from Alzheimer's treatments...
- \$270-\$300 million more from arthritis and other autoimmune diseases...

That's a \$620 million to \$725 million range...

The *Money Morning* Prospectus discusses the specific timelines for each revenue stream. It has detailed charts and projections.

And after reviewing everything carefully what you'll see is that, at its full potential, with this company, we're talking about 23,474% growth or more.

And the value of your former round lots – which will become NASDAQ shares – should rise right along with this growth.

Okay, so besides the normal capital gains, which by all accounts should be historic, there is also a powerful tax incentive the government has put in play.

To claim it you will just need to fill out a simple form and send it in. We've provided the form in the *Money Morning* Prospectus package.

This credit alone has the potential to put thousands, even tens of thousands, of dollars of profits back into your pocket.

Say for example, you turn 20 round lots – just a \$2,000 stake – into a \$30,000 windfall...

By sending the simple form I'm including in this package to the IRS, they will cut you a check back for \$4,200.

So think about that.

The IRS would pay you almost \$2,200 more than you originally invested into this company.

It's icing on the cake – on top of the already amazing capital gains you would've received.

Now, there is one final question I want to focus on.

Question #4: Will I Receive Any Help Managing This Investment?

The answer is you are 100% in control of this venture.

You call the shots.

However, here at *Money Morning*, we prefer to take a hands-on approach with the unconventional opportunities and research we bring our members.

We do this because we want to ensure folks maximize their rewards.

It's why we are there every step of the way assisting you.

And it's why I'd like you to join us.

My aim is to keep members up to date on this biotech firm's progress in getting listed on the NASDAQ, as well as a host of other opportunities that we'll be moving into.

I'll give you real-time updates, via email, on their most successful clinical trials and promising drug applications.

I'll alert you to every FDA drug approval announcement the second they're released.

And, when it's time to cash out, I'll send you an alert then as well.

I will take you from A to Z so you get the optimal windfall profit from this opportunity.

This is how we handle all the unconventional investments we bring across the board to members here at *Money Morning*.

Let me show you what I mean.

Not too long ago, I met with a senior advisor to Rare Element Resources LTD.

As the name suggests, Rare Element Resources is a leader in rare earth metals.

These are a critical resource that's in nearly every piece of modern electronics. But only a few companies have a stranglehold on their production and supply.

And Rare Element Resources was one of them.

With the help of this senior advisor, I was able to bring, not just this company to members, but 3 other leaders in rare earth metals.

Those companies were Avalon Rare Metals, Inc., Quest Rare Minerals, and Great Western Minerals Group, Ltd.

I put together a comprehensive presentation on these companies – I led folks into each of them – I guided them through the whole process – and in a matter of months, I instructed members that it was time we grab our profits.

Which is exactly what we did... Cashing out for total gains of 990%.

Here's another example.

You've probably heard of the controversial virtual currency, Bitcoin.

Well last year, out in Silicon Valley, I met with the CEOs and venture capitalists who were developing Bitcoin exchanges and investment funds.

And through this work I could tell that we were about to see an aggressive spike in its popularity.

So in June of 2013 I filmed a tutorial video for *Money Morning* members that showed them step by step how to properly get set up with a Bitcoin trading account – I identified which trades to target – and I identified how to handle the gains from a tax perspective.

Bitcoin was trading for \$90 then.

And over the next five months, Bitcoin skyrocketed 1,192%.

Then there's the incredible profits we were able to offer our members from a new innovative "fuel injection system" called CFIS technology.

This technology was invented and controlled by a small company called Westport Innovations.

And it was about to be licensed by GM for use in ALL of their vehicles.

So we alerted our members to this opportunity. And because of our recommendation...

Members Had The Chance to Capture Total Gains of **1,116%**

Now before I show you how we're going to handle this Living Metal venture, let me just share one more example with you.

In December, the team I help lead here at *Money Morning* worked directly with the CEO of Silver Tusk Oil Field to negotiate an exclusive deal that gave our members the chance to purchase a **direct stake** in an oil well.

It is located at the Sand Lake Prospect in Burleson County, Texas.

It's a claim with a *known* supply of over a billion barrels of oil, plus 4.5 trillion cubic feet of natural gas.

As owners, these folks were given access to the company by a private concierge phone line and can actually visit the oil well if they so choose.

Here's the deal we negotiated... once the well began producing, *Money Morning* members would get a cut of the income, paid monthly for up to 20 years.

In May, the first exploratory well struck a rich vein of oil!

The oil is on the market, they're already producing 4,200 barrel per week – and the first checks are being delivered this month.

Every step of the way, every development, every new well they start digging – we're guiding our members through this venture – *because they're the owners of it.*

And I expect this Living Metal opportunity will be no different.

If you decide to secure round lots in this company, you will be taking an ownership stake in it.

And I'm going to make sure you get all the help you need in capitalizing on it.

The first step is to FedEx overnight your *Money Morning* Prospectus. You'll receive that within 24 hours.

You will also receive the audio briefing with the CEO and myself, as well as the form you'll need to send the IRS for the tax credit.

You'll receive all of this, as well as my expertise, through a research service I've set up called...

Radical Technology Profits.

Radical Technology Profits helps everyday investors get in on the ground floor of explosive

opportunities in biotech, military defense, supercomputing, 3D printing, and every other cutting-edge breakthrough that is seeing a flood of venture capital funding.

The company with a monopoly on this Living Metal is a perfect match.

But it's not the only one we'll be targeting.

On average, you'll receive four new investment briefings every month through **Radical Technology Profits**.

For example:

- We just targeted a small-cap company that has created a technology called a *Complementary Metal-Oxide-Semiconductor*.

Google and NASA have just teamed up to build a device using this technology that can create a real-time 3D map of your surroundings.

NASA is planning on using this technology to allow their rovers to construct detailed maps of their surroundings on other planets.

That's exciting stuff.

But Google is why we're going to make money on this... Because they're pushing to get this device into every one of their Android mobile-operating platforms around the world.

I'm talking about cell phones, tablets, computers, even their new automotive operating system.

- Last year, my work took me to a small biotech company called Inovio.

Inovio had patented a process for developing synthetic vaccines.

While it was in the early stages of investigative clinical trials, I had dinner with the company's CEO – Joseph Kim.

Because of the exceptional early results of Inovio's clinical trials, Roche entered into a licensing deal with them worth as much as \$422 million.

- **Radical Technology Profits** members also got the chance to get in early on an innovation that's about to revolutionize the world of medical imaging.

Instead of simply taking an MRI, which is what current technologies do...

One company's MRI machines can analyze the results and point out even the most minute problems that a doctor could overlook.

According to a new study in the *Journal of Patient Safety*, as many as 440,000 people die a year due to medical error.

This device could dramatically lower that number.

Now, 3D printing is a buzzword in technology these days. But what you may not have heard about is 3D bioprinting.

This is an exciting new development in medicine where doctors use a person's own cells to bioengineer donor tissue.

This will save many lives, because one of the biggest risks during an organ transplant, or tissue transplant, is the body rejecting what it views as a "foreign substance."

But when it's your own tissue being implanted, this eliminates the problem.

This was a medical breakthrough whose time had come, which is why I got a lot of folks into the one company who controls this technology.

Now, let me tell you about another opportunity I'm really excited about... and I believe is going to pay off big time for **Radical Technology Profits** members.

It's a tiny biotech firm that has a deep pipeline of drugs for sleep aids, antibiotics for ear infections and cough and cold medicines...

However, it's not the drugs or patents that caught my attention in this case...

It's the new CEO.

His name is Doug Drysdale... and for the past 25 years, I've watched Doug turn small pharmaceutical companies and biotech firms into multinational behemoths.

His last project was Alvogen. He took the company from inception to now operating in 30 different countries with a pipeline of 200 drugs.

Before that, he was an executive at Actavis pharmaceuticals. His work in strategic partnerships and acquisitions helped drive their stock from as low as \$23 to over \$221 today.

That's a 944% spike.

And, at his new position he's poised to do the same thing.

He's already brokered major drug acquisitions with GlaxoSmithKline and Pfizer... and investors are pouring money into the company behind him.

\$65 million since he came on board earlier this year.

This is what I do with ***Radical Technology Profits***.

And I'm there with you every step of the way to help you manage these plays.

Now along with the four monthly investment research briefings, you will also receive instant sell alerts.

So when it's time to exit any opportunity and collect maximum profits, I send you an additional alert via email.

You can also have these sent to your cell phone via text message, so you can ensure you receive these instructions as fast as possible.

Members are also sent weekly intelligence rundowns that explore the economy, the markets, the groundbreaking technologies that are being developed, and, of course, our current investment opportunities.

In addition, I record audio and video reports of my meetings with the CEOs and innovators at the companies we're targeting.

Plus, you'll have 24/7 access to the ***Radical Technology Profits*** website where every communication is archived, and you can constantly monitor a real-time review of all of our open positions.

And to answer any, and all, of your questions about the service, I have a members' concierge service set up.

You can call 9-5, Monday through Friday (Eastern Time) – and be sure to mention Priority Code ETIMQ811.

This hands-on approach to investing is why – in just a little over two years – I've been able to deliver ***Radical Technology Profits*** members 44 double- and triple-digit winners.

And Overall, Members are Currently Experiencing a 87.5% Win Rate on Open Investments

For members like Bob Kreen of St. Louis, MO this has resulted in a dramatic transformation of their wealth.

Bob told me...

"Since joining a year ago, I've tripled my net worth"
– Bob Kreen

And then there's Alvin Canone who has a similar story. He says...

"Michael, you have doubled my money!"

– Alvin Canone

And Carter Roberts tells me that in just one calendar year...

"I made approximately \$125,000!"

– Carter Roberts

I'd like to officially invite you to accept one of the *Money Morning* Prospectuses I'm releasing – and FedEx overnighting – today.

This will give you everything you need to take advantage of the biotech firm that currently has a monopoly on this Living Metal.

Remember, MCh will soon be at the center of lifesaving treatments for Alzheimer's disease, cancer, C. Diff and countless others.

You will be able to jump on board **BEFORE** this company goes public on the NASDAQ.

The *Money Morning* Prospectus will give you a comprehensive examination of the company's projected revenue streams, its technologies, its executive and scientific boards...

And it will track the progress of all 124 active clinical trials.

The accompanying audio briefing with the CEO and myself will delve further into this venture.

And most important, you'll be provided with step-by-step instructions on how to secure round lots in this company

Each round lot will become 100 shares once it's listed on the NASDAQ exchange, as soon as August 31st.

The *Money Morning* Prospectus includes phone numbers where you can secure these round lots.

If you want to purchase them online, you'll be shown where to do so.

The package even includes the form you'll need to send to the IRS to claim the lucrative tax credit that will be made available to you.

You can get all of this as a member of **Radical Technology Profits**, as well as my expertise with you for every step of it.

Plus, many more unconventional and highly profitable opportunities like it.

There is a button at the end of this letter that will take you to the non-disclosure and membership form that you will need to review and fill out before you can receive the *Money Morning* Prospectus.

It will explain many other critical details about this opportunity but here's one I want to point out now before you click this button.

For full disclosure I do not, nor does anyone at *Money Morning*, currently have any round lots in this biotech firm.

This provides you with an extra level of assurance that there are no conflicts of interest involved.

When you click the button at the end of this letter the costs for receiving a membership to *Radical Technology Profits*, which includes the *Money Morning* Prospectus package will also be explained.

And so will the following three guarantees I've put in place for your protection.

Guarantee #1: If You Feel This Opportunity Isn't Right For You During the Next 30 Days – You Pay Nothing.

I encourage you to review my research, and the *Money Morning* Prospectus, and decide whether this is something that fits your goals.

Then take the next 30 days to analyze *Radical Technology Profits*.

You'll have full access to every investment briefings I release.

You'll receive my weekly market analysis.

You can review all of my investment reports on the *Radical Technology Profits* opportunities I've discussed throughout this presentation.

You can listen to my audio briefings and take full advantage of the video training I provide inside your members' only website.

Plus, you should utilize the private, phone concierge service I've created to assist you.

In fact, I'll include the business card of your contact inside the company in your *Money Morning* Prospectus so you'll know who you're talking to when you call.

If for any reason, you feel this isn't right for you, simply contact us and we'll refund every penny you paid.

Now, this second guarantee will truly show you how serious I am.

Guarantee #2: This Living Metal Company Will Get Listed on the NASDAQ By November 30th... or I'll Work For Free

Remember, according to the NASDAQ's corporate governance, this company's share price MUST be initially listed at \$3 or higher.

And right now you can purchase each round lot for \$100... but by the time this company is listed on the NASDAQ, each round lot you hold could be valued at \$300.

Now, you heard the CEO say that listing is going to happen within weeks.

He's said it should happen by the end of this company's financial year – August 31st.

However, if the SEC or NASDAQ have any issues, they could delay that launch.

If that were to happen – which is unlikely – I believe they would certainly be listed by the end of their first financial quarter.

That's November 30, 2014.

So, if this company isn't listed on the NASDAQ by November 30th, I'll extend your membership to **Radical Technology Profits** another year on the house.

Now, I have one more layer of protection that backs up everything I've told you today.

Guarantee #3: We'll See a Commercialized Drug Deliver Explosive Growth to This Company Within 1 Year, or I'll Work For Free

In today's presentation I revealed how this company developed a monopoly on MCh, our Living Metal...

I showed you the stunning way it could conquer Alzheimer's disease, cancer, and even stop a pandemic like Ebola.

And I've shown you the statistical proof that at least 7 of its drugs should reach commercialization within the next 15 months.

When that happens, it could propel this company from \$2.63 million in cumulative sales to at least \$620 million a year.

But all it takes is 1 drug to get this all going.

- \$10 million could come from this Living Metal being integrated into immunology therapy – that alone would boost the company's revenue 3-fold.
- \$40 million in revenue from a single cancer treatment – that would be a 15-fold increase...
- \$100 million from their C. Diff treatment would – all by itself – represent a 38-fold revenue boost.
- \$200 million from Alzheimer's treatments would equal a 76-fold spike.

- And we could see \$270 million from a Living Metal treatment for autoimmune diseases like arthritis. That would be the equivalent of a 102-fold leap in revenue.

And I fully expect we'll see numerous drugs reach commercialization within the next year.

So if for some reason, one doesn't reach commercialization before July 2015 – I'll work for free... I'll extend your membership another 12 months at no charge.

I'm only making this opportunity available to a few folks who can see the true size and scope of this opportunity.

I'm ONLY offering this *Money Morning* Prospectus, included with a membership to **Radical Technology Profits** to folks who make the decision to join today.

These spots won't last long, and there's no guarantee if I'll be able to send out more, so *Money Morning* Prospectuses will go out so long as supplies last and are first come, first served.

So click the button below this letter and you'll be taken directly to the nondisclosure agreement and membership form.

Or if you'd prefer to join by phone, please contact our VIP Member Services team at 1-855-509-6600 (1-410-622-3004 for international callers) and mention your Priority Code: ETIMQ811. They'll answer any questions you may have and sign you up right away.

I want to thank you for participating in this presentation.

I'm Michael Robinson. Good day.

Sincerely,



Michael A. Robinson
Director of Venture Capital and Technology Investing
Money Morning
July 2014

[JOIN NOW](#)

Copyright - 2014 Money Map Press, LLC. The Money Map Press is a publishing company that does not act as a personal investment advisor for any specific individual. Nor do we advocate the purchase or sale of any security or investment for any specific individual. The proprietary recommendations and analysis we present to readers is for the exclusive use of subscribers. Readers should be aware that although our track record is highly rated, and has been legally reviewed for presentation in this invitation, investment markets have inherent risks and there can be no guarantee of future profits. Likewise, our past performance does not assure the same future results. Warning: The past performance of any trade whether actual or hypothetical is not necessarily an indication of future results. Stocks, futures, currencies, commodities, CFDs, options and all types of investment trading can have large potential rewards, but also carry large potential risks. We make absolutely no representation that gains or losses demonstrated in services published by Money Map Press LLC are likely or achievable. Hypothetical trading examples also cannot possibly take into account the impact of liquidity or buyer and seller demand, and do not allow for slippage and associated trading costs and concerns. One must be aware of the risks and be willing to accept them in order to invest in the markets. One should never trade with money that one cannot afford to lose, and one must accept that there will be losses, and one must be able to sustain these losses, both from a financial as well as an emotional perspective. Recommendations are for the exclusive use of subscribers and can change at any time. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.